Boston Scientific Reports Positive EKOS System Clinical Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy BSX?
Source: NASDAQ.COM
- Clinical Trial Success: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS Endovascular System combined with anticoagulation met the composite primary endpoint, proving superior to the current standard of care for acute pulmonary embolism treatment.
- Significant Treatment Effects: The study revealed that the EKOS system effectively improves treatment outcomes for intermediate-risk pulmonary embolism patients by delivering a low dose of clot-dissolving medication directly to the clot and utilizing ultrasound energy to enhance medication dispersion, thereby reducing cardiovascular mortality.
- Guideline Updates Expected: Current medical guidelines recommend anticoagulation for all risk levels of pulmonary embolism, and the successful application of the EKOS system may prompt updates to these guidelines, facilitating broader clinical adoption.
- Market Potential: Given that pulmonary embolism is the third leading cause of cardiovascular mortality, the clinical success of the EKOS system not only opens new market opportunities for Boston Scientific but could also significantly enhance its market share in the cardiovascular sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
Current: 70.170
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific's CHAMPION-AF Trial Achieves Success
- Trial Success: Boston Scientific announced that its CHAMPION-AF global clinical trial successfully met all primary and secondary safety and efficacy endpoints, indicating a promising future for the WATCHMAN FLX device in non-valvular atrial fibrillation patients.
- Device Superiority: Key findings revealed that the WATCHMAN FLX device provided statistically superior protection from bleeding while demonstrating similar efficacy to non-vitamin K antagonist oral anticoagulants in reducing stroke risk, highlighting its potential as a first-line therapy.
- Academic Validation: The results were presented as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session & Expo and were simultaneously published in The New England Journal of Medicine, enhancing the credibility of WATCHMAN FLX as a safe and effective alternative to long-term anticoagulant therapy.
- Market Reaction: Despite the trial's success, Boston Scientific's stock price fell by 1.43% to $69.17 in Friday's regular trading, indicating a cautious market response to the news.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased the company's securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements during this period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading investors to misunderstand the company's prospects.
- Market Reaction: The lawsuit highlights that the company is experiencing adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, indicating that the growth inflection point for the electrophysiology segment occurred earlier than the market anticipated, impacting investor confidence.
- Investor Rights Protection: The law firm representing the plaintiffs offers legal services on a contingency fee basis, meaning they will only charge fees if successful, ensuring that investors do not incur additional costs in the lawsuit.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this timeline critical for potential claims.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
Boston Scientific Reports Positive EKOS System Clinical Trial Results
- Clinical Trial Success: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS Endovascular System combined with anticoagulation met the composite primary endpoint, proving superior to the current standard of care for acute pulmonary embolism treatment.
- Significant Treatment Effects: The study revealed that the EKOS system effectively improves treatment outcomes for intermediate-risk pulmonary embolism patients by delivering a low dose of clot-dissolving medication directly to the clot and utilizing ultrasound energy to enhance medication dispersion, thereby reducing cardiovascular mortality.
- Guideline Updates Expected: Current medical guidelines recommend anticoagulation for all risk levels of pulmonary embolism, and the successful application of the EKOS system may prompt updates to these guidelines, facilitating broader clinical adoption.
- Market Potential: Given that pulmonary embolism is the third leading cause of cardiovascular mortality, the clinical success of the EKOS system not only opens new market opportunities for Boston Scientific but could also significantly enhance its market share in the cardiovascular sector.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Success: Boston Scientific announced that its WATCHMAN FLX device successfully met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating similar efficacy to anticoagulants in patients with non-valvular atrial fibrillation, potentially transforming stroke risk reduction treatment strategies.
- Bleeding Risk Comparison: The trial results indicated a major bleeding event rate of 5.9% for the WATCHMAN FLX device at 36 months, statistically non-inferior to the 6.4% rate for anticoagulants (P<0.001), providing strong support for its use as a first-line treatment option.
- Broad Applicability: The CHAMPION-AF trial is the largest study to date comparing LAAC devices to anticoagulants, involving 3,000 patients from 141 sites, with a 99% procedural success rate, showcasing the device's broad applicability and reliability.
- Future Outlook: Boston Scientific plans to leverage these positive data to support updates to global clinical guidelines and expand indications for the WATCHMAN platform, aiming to provide more treatment options for a growing number of atrial fibrillation patients and reduce stroke risk.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the WATCHMAN FLX Left Atrial Appendage Closure device met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating its superiority in patients with non-valvular atrial fibrillation.
- Bleeding Risk Reduction: The trial results indicated that the WATCHMAN FLX device had a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, achieving a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: The WATCHMAN FLX device showed a stroke, cardiovascular or unexplained death, and systemic embolism occurrence rate of 5.7%, compared to 4.8% for NOACs, demonstrating statistical non-inferiority and reinforcing its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of an LAAC device to NOACs to date, involving 141 sites and achieving a 99% procedural success rate, providing robust support for future updates to clinical guidelines.
See More
Boston Scientific's CHAMPION-AF Trial Achieves Success
- Trial Success: Boston Scientific announced that its CHAMPION-AF global clinical trial successfully met all primary and secondary safety and efficacy endpoints, indicating a promising future for the WATCHMAN FLX device in non-valvular atrial fibrillation patients.
- Device Superiority: Key findings revealed that the WATCHMAN FLX device provided statistically superior protection from bleeding while demonstrating similar efficacy to non-vitamin K antagonist oral anticoagulants in reducing stroke risk, highlighting its potential as a first-line therapy.
- Academic Validation: The results were presented as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session & Expo and were simultaneously published in The New England Journal of Medicine, enhancing the credibility of WATCHMAN FLX as a safe and effective alternative to long-term anticoagulant therapy.
- Market Reaction: Despite the trial's success, Boston Scientific's stock price fell by 1.43% to $69.17 in Friday's regular trading, indicating a cautious market response to the news.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased the company's securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that executives made materially false and misleading statements during this period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading investors to misunderstand the company's prospects.
- Market Reaction: The lawsuit highlights that the company is experiencing adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, indicating that the growth inflection point for the electrophysiology segment occurred earlier than the market anticipated, impacting investor confidence.
- Investor Rights Protection: The law firm representing the plaintiffs offers legal services on a contingency fee basis, meaning they will only charge fees if successful, ensuring that investors do not incur additional costs in the lawsuit.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this timeline critical for potential claims.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, ensuring their rights are protected in the securities market.
See More
Boston Scientific Reports Positive EKOS System Clinical Trial Results
- Clinical Trial Success: Boston Scientific's HI-PEITHO global randomized trial demonstrated that the EKOS Endovascular System combined with anticoagulation met the composite primary endpoint, proving superior to the current standard of care for acute pulmonary embolism treatment.
- Significant Treatment Effects: The study revealed that the EKOS system effectively improves treatment outcomes for intermediate-risk pulmonary embolism patients by delivering a low dose of clot-dissolving medication directly to the clot and utilizing ultrasound energy to enhance medication dispersion, thereby reducing cardiovascular mortality.
- Guideline Updates Expected: Current medical guidelines recommend anticoagulation for all risk levels of pulmonary embolism, and the successful application of the EKOS system may prompt updates to these guidelines, facilitating broader clinical adoption.
- Market Potential: Given that pulmonary embolism is the third leading cause of cardiovascular mortality, the clinical success of the EKOS system not only opens new market opportunities for Boston Scientific but could also significantly enhance its market share in the cardiovascular sector.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Success: Boston Scientific announced that its WATCHMAN FLX device successfully met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating similar efficacy to anticoagulants in patients with non-valvular atrial fibrillation, potentially transforming stroke risk reduction treatment strategies.
- Bleeding Risk Comparison: The trial results indicated a major bleeding event rate of 5.9% for the WATCHMAN FLX device at 36 months, statistically non-inferior to the 6.4% rate for anticoagulants (P<0.001), providing strong support for its use as a first-line treatment option.
- Broad Applicability: The CHAMPION-AF trial is the largest study to date comparing LAAC devices to anticoagulants, involving 3,000 patients from 141 sites, with a 99% procedural success rate, showcasing the device's broad applicability and reliability.
- Future Outlook: Boston Scientific plans to leverage these positive data to support updates to global clinical guidelines and expand indications for the WATCHMAN platform, aiming to provide more treatment options for a growing number of atrial fibrillation patients and reduce stroke risk.
See More
WATCHMAN FLX Device Clinical Trial Achieves Success
- Clinical Trial Results: Boston Scientific announced that the WATCHMAN FLX Left Atrial Appendage Closure device met all primary and secondary safety and efficacy endpoints in the CHAMPION-AF global clinical trial, demonstrating its superiority in patients with non-valvular atrial fibrillation.
- Bleeding Risk Reduction: The trial results indicated that the WATCHMAN FLX device had a non-procedural major and clinically relevant non-major bleeding rate of 10.9%, significantly lower than NOACs at 19.0%, achieving a 45% relative risk reduction, highlighting its advantages in bleeding management.
- Efficacy Comparison: The WATCHMAN FLX device showed a stroke, cardiovascular or unexplained death, and systemic embolism occurrence rate of 5.7%, compared to 4.8% for NOACs, demonstrating statistical non-inferiority and reinforcing its potential as a first-line treatment option.
- Global Impact: This trial is the largest comparison of an LAAC device to NOACs to date, involving 141 sites and achieving a 99% procedural success rate, providing robust support for future updates to clinical guidelines.
See More
